Opioid antagonists, partial agonists, and agonists/antagonists: The role of office-based detoxification

Pain Physician

Volumn 11, Issue 2, 2008, Pages 225-235

  Helm II, Standiford ^a   Trescot, Andrea M ^b   Colson, James ^c   Sehgal, Nalini ^d   Silverman, Sanford ^e  

^a Pacific Coast Pain Management Center   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e Medical Director Comprehensive Pain Management of North Florida   (United States)

Author keywords

Antagonist; Buprenorphine; Butorphanol; Dependence; Detoxification; Hyperalgesia; Methylnaltrexone; Nalbuphine; Naloxone; Naltrexone; Opioid; Partial agonist; Pentazocine; Tolerance; Withdrawal

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; HYDROMORPHONE; ILLICIT DRUG; LEVACETYLMETHADOL; LOFEXIDINE; METHADONE; MORPHINE; NALOXONE; NALTREXONE; OPIATE AGONIST; OPIATE ANTAGONIST; OXYCODONE; OXYTREX; PLACEBO; TRAMADOL; UNCLASSIFIED DRUG;

BEHAVIOR THERAPY; CLINICAL TRIAL; DETOXIFICATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EMBASE; HEROIN DEPENDENCE; HIGH RISK BEHAVIOR; HIP OSTEOARTHRITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KNEE OSTEOARTHRITIS; MEDLINE; METHADONE TREATMENT; MONOTHERAPY; OPIATE ADDICTION; OUTPATIENT CARE; PSYCHOSOCIAL CARE; REVIEW; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; DRUG AND NARCOTIC CONTROL; EVALUATION STUDIES AS TOPIC; HUMANS; METABOLIC DETOXICATION, DRUG; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 42249090335     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Gal TJ, DiFazio CA, Dixon R. Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther 1986; 40:537-542.
2. Tamaskar R, Parran TV, Jr, Heggi A, Brateanu A, Rabb M, Yu J. Tramadol versus buprenorphine for the treatment of opiate withdrawah A retrospective cohort control study. J Addict Dis 2003; 22:5-12.
3. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: A systematic review. J Pain Symptom Manage 2007; 34:547-565.
4. Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: A; randomized, controlled trial of Oxytrex. J Poin 2005; 6:392-399.
5. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63:210-218.
6. Mitchell TB, White JM, Somogyi AA, Bochner F. Slow-release oral morphine versus methadone: A crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction 2004; 99:940-945.
7. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267:2750-2755.
8. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998; 93:475-486.
9. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343:1290-1297.
10. Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 2002; 97:1395-1404.
11. Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: A novel study. Eur ] Clin Invest 2003; 33:824-829.
12. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang. CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349:949-958.
13. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98:441-452.
14. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet 2003; 361:662-668.
15. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005; 100:1090-1100.
16. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, Brooklyn J. Comparison of pharmacological treatments for opioid-dependent adolescents: A randomized controlled trial. Arch Gen Psychiatry 2005; 62:1157-1164.
17. Raistrick D, West D, Finnegan O, Thistlethwaite G, Brearley R, Banbery J. A comparison of buprenorphine and lofexidine for community opiate detoxification: Results from a randomized com trolled trial. Addiction 2005; 100:1860-1867.
18. Gowing L, Ali R, White J. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev 2006; 1:CD002021.
19. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? Drug Alcohol Depend 2005; 79:113-116.
20. Correia CJ, Walsh SL, Bigelow GE, Strain EC. Effects associated with doubleblind omission of buprenorphine/naloxone over a 98-h period. Psychopharmocology (Berl) 2006; 189:297-306.
21. Gerra G, Fantoma A, Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 2006; 20:806-814.